PREPARE AND EVALUATE MUCOADHESIVE FORMULATIONS OF LAMIVUDINE WITH BETTER CONTROLLED/ SUSTAINED DRUG RELEASE PROFILE by Rathore, Kavita et al.
Rathore et al                                                                                                   Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):694-700 
ISSN: 2250-1177                                                                                  [694]                                                                                 CODEN (USA): JDDTAO 
Available online on 30.08.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
Prepare and Evaluate Mucoadhesive Formulations of Lamivudine with 
Better Controlled/ Sustained Drug Release Profile 
Kavita Rathore, C.K. Tyagi, Harish Pandey, Sunil Kumar Shah * 
Department of Pharmaceutics, College of Pharmacy, Sri Satya Sai University of Technology & Medical Sciences, Sehore, Madhya Pradesh, India.  
 
ABSTRACT 
The aim of present study was to formulate & evaluate the mucoadhesive sustained release formulations of lamivudine and to fulfill this aim, two 
mucoadhesive formulations Gels and Tablets were prepared by using three different polymers: HPMC K15, poloxamer 407 & carbopol 934. 
Three mucoadhesive gel and nine tablet formulations were prepared and evaluated for various parameters. All three gels were able to give 
sustained release up to 12 hours. Tablet formulations, F1 to F5 failed to fulfill the aim. Only F6, F7, F8 & F9 formulations were selected, as all 
gave sustained release up to 12 hours, except F6, which gave sustained release profile only till 7 hours. From the drug release plots, it was 
concluded that the type of polymer and concentration of polymer have distinct effect on in vitro drug release profile and all  the formulations 
follow first order mechanism with anomalous diffusion or non-fickian diffusion, except carbopol gel and poloxamer tablets. Carbopol gel follows 
zero order release rate with super case II transport and poloxamer tablets (F6) follow higuchi with non-fickian diffusion. It is concluded that 
mucoadhesive formulations of lamivudine can be prepared for sustaining its release. And the successful outcome of the present study also 
encourage for further studies to assess the ability of the mucoadhesive formulations of lamivudine in providing an effective sustained and safe 
therapy for AIDS. 
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INTRODUCTION 
The principle of mucoadhesive preparation is simple 
practical approach and is particularly useful to prolong the 
retention time of a dosage form in the stomach and 
improving the oral bioavailability of the drug1.The aim was 
to develop drug delivery systems that would increase the 
absorption of a drug for both local and systemic effects as a 
result of intimate and prolonged contact at the site of 
absorption2-4. Among the early work on bioadhesive systems 
is that of Nagai and coworkers, who showed that the 
treatment was improved for several administration routes 
when adhesive formulations were used5. For example, the 
treatment of aphthae, an infection in the mouth, and the 
treatment of uterine cancer were improved with local 
delivery using mucoadhesive tablets. In addition, 
mucoadhesive preparations for delivery of insulin through 
the buccal and the nasal routes of administration were 
investigated6,7. The term mucoadhesion appeared in the 
literature for the first time in 1977. In a medical research 
paper describing a clinical trial of a locally delivered 
anaesthetic.  In the mid and late 1980s the concept of 
mucoadhesion became more commonly recognised9. Over 
the years, mucoadhesive and bioadhesive systems have been 
used for NDDS, ODDS, BDDS, vaginal, rectal and oral drug 
delivery10.  
Nowadays, mucoadhesion in the literature, covering a wide 
variety of applications11. In some studies, the term 
mucoadhesive formulation is used in a routine and 
noncritical way, e.g. different formulations and polymers 
have been ranked as more or less mucoadhesive by using 
randomly chosen methods12-16.  polymers have been 
developed and used with the intention of learning more 
about the kind of interactions that can occur between the 
formulation and the mucosa17. But even now, the 
understanding of the phenomenon is not yet complete18. One 
of the reasons for this is probably that there are so many 
different formulations involving a large variety of adhesion 
mechanisms that no single existing theory can explain them 
all. In our present work we are preparing two different types 
of mucoadhesive formulations-mucoadhesive gel and 
mucoadhesive tablets19-20. 
MATERIALS  
Materials used in this study were obtained from the different 
sources.  Lamivudine was a gift sample from Cipla indore 
Madhya Pradesh, India. Carbopol 974P and Xanthan gum 
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were procured from Loba Chemie Pvt.Ltd, Mumbai.  Other 
excipients such as Aerosil and magnesium stearate were 
procured from Alfa Laboratories, Mumbai. 
METHODS OF PREPARATION OF MUCOADHESIVE GELS: 
Preparation of Lamivudine Gel by Using HPMC K15: 
2%, 4%, 6%, 8%, 10% & 12%, plane gel formulation of 
HPMC K15 were prepared in distilled water by simple 
mixing method21-23. 12%, formulation was selected on the 
bases of consistency of gel. Lamivudine (150mg) was 
dissolved in small amount of distilled water and then 
incorporated in 12% HPMC gel with continuous stirring. 
After that, set aside the formulation for some time at room 
temperature24,25. 
Preparation of Lamivudine Gel by Using Corbopol 934: 
0.5, 1% & 2%, plane gel formulation of Carbopol were 
prepared in distilled water. Out of these, 1% gel formulation 
was selected on the bases of gel consistency26,27. As on 
incorporation of lamivudine (150mg), the formulation was 
precipitated28,29. Therefore 0.5% gel was selected to get the 
desired gel formulation. And gel was prepared by simply 
adding the lamivudine (already dissolved in small amount of 
water) into 0.5% carbopol gel, with continuous stirring30. 
Preparation of Lamivudine gel by using POLOXAMER 407:  
The Pluronic F127 (Poloxamer 407) were prepared by 
modification of the “Cold dispersion” method described by 
Schmolka. The weighed amount of poloxamer (1g) was 
placed in beaker and left in an oven at 110°C for 15 minutes 
to obtain a homogeneous liquefied mixture then 150mg 
lamivudine (which was already dissolved in small amount of 
water) added with continuous stirring31. The solution was 
cooled to room temperature, & beaker was left in a 
refrigerator until a clear solution was obtained. The gel was 
formed when the solution was brought back to room 
temperature and stored at ambient temperature prior to use. 
Formulation of Mucoadhesive Tablets: 
Mucoadhesive tablets of Lamivudine were made by direct 
compression method. Nine formulations (F1-F9) were 
formulated by using three different mucoadhesive polymers 
(HPMC K15, Carbopol 934 & Poloxamer 407). Mucoadhesive 
polymers were used as binder, lactose as diluents and talc as 
lubricant32. 
The mucoadhesive tablets were prepared by mixing of drug 
with binder, in a pestle and mortar until homogenized. Then 
all other excipients were added. Mixture was passed through 
sieve no. 60. Finally the blend was compressed using the 
round concave punches (10.3mm in diameter) and dies by 
rotary tablet punching machine33. The tablet weight was 
adjusted to 500mg and 75 tablets for each batch were 
prepared.  Formula for nine batches is given in table 1. 
  
Table 1: Formula for different tablet formulations. 
INGREDENTS 
(mg) 
FORMULATION 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Drug (Lamivudine) 150 150 150 150 150 150 150 150 150 
HPMC K 15 100 150 200 - - - - - - 
Carbopol 934 - - - - - - 20 30 40 
Poloxamer 407 - - - 75 125 175 - - - 
Lactose 230 180 130 255 205 155 310 300 290 
Talc 20 20 20 20 20 20 20 20 20 
 
EVALUATION PARAMETER FOR MUCOADHESIVE GELS34-
36:  
General Appearance:  
A Visual inspection was done to know the general 
appearance of gels. There should be no sign of grittiness and 
formulation must be of uniform texture. 
Mucoadhesive Force: 
Mucoadhesive force of all three gel formulation was 
determined by method and  apparatus reported by Choi et 
al., 1998 & koffi et al, 2006. (by using goat stomach mucosa). 
Drug Release Profile: 
Drug release profile of all three gel formulations was carried 
out in distilled water, by using cellophane membrane and 
drug release rate kinetics of the formulations was 
determined by fitting release result in models of data 
treatment as follows: 
1. Log cumulative percent drug remaining versus time (first 
order kinetic model). 
2. Cumulative percent drug release versus time (zero order 
kinetic model). 
3. Higuchi release kinetic model. 
4. Korsmeyer- peppas model. 
EVALUATION PARAMETER FOR MUCOADHESIVE 
TABLETS37,38: 
General Appearance: 
General appearance was examined by visual inspection. All 
tablets should be of uniform size, shape, color and surface 
textures etc. 
Weight variation: 
Randomly, twenty tablets were selected and individually 
weighed. The average weight of tablet was calculated. Then 
individual weight was compared with average weight of 
tablets. It should be within the range ±5 for tablet more than 
324mg. 
Thickness:  
Six tablets were selected randomly from each batch and 
thickness was measured by using vernical caliper. 
Friability: 
Twenty tablets were weighted and placed in Roche 
friabilator and equipment was rotated at 25 rpm for 4 
minute. The tablets were taken out, dusted and reweighed. 
The percentage friability of tablets should be within range of 
±1.  
Hardness:   
Hardness was determined by using Monsanto Hardness 
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tester. Six tablets from each batch were tested randomly and 
the average reading noted. 
Swelling index: 
Swelling index was determined by method as descried 
earlier for three tablets of each batch. i.e. tablet was weighed 
and placed in a beaker containing 200 ml of distilled water. 
The tablet was gently removed at time intervals such as 1, 10 
and 20mins, blotted dry and the weight determined. This 
was stopped once the tablets start eroding or became too 
gelatinous and swelling index was calculated. 
Mucoadhesive Strength: 
Mucoadhesive strength of tablets was measured on the 
modified physical balance as described earlier by using goat 
stomach mucosa. 
Drug Content: 
Take 100mg equivalent weight of crushed powder of tablets 
and dissolved in 1000ml of distilled water. Solution was 
filtered and diluted appropriately. Then, solution was 
analyzed by UV Spectrophotometer at λ max.  
In-vitro dissolution studies and release kinetic analysis: 
In vitro release rate study of mucoadhesive tablet was 
carried out by using the Apparatus 2 i.e. Basket apparatus, 
using distilled water as dissolution media. And absorbance 
of samples was measured at λ max. To analyze the drug 
release rate kinetics of the formulations, the results of in-
vitro release profiles were fitted to following models. 
1. Log cumulative percent drug remaining versus time 
(first order kinetic model). 
2. Cumulative percent drug release versus time (zero 
order kinetic model). 
3. Higuchi release kinetic model. 
4. Korsmeyer-peppas model. 
RESULT AND DISCUSSSION 
Preliminary Investigation of Drug (Lamivudine):  
Physical Appearance 
Lamivudine was white color powder.   
Melting Point 
Melting point of lamivudine was found to be 161°C. 
Solubility study 
Solubility profile of lamivudine in various solvents, are given 
in table 2. 
Table 2: Solubility profile of Lamivudine in various 
solvents 
S. No. Solvent Solubility 
1 Distilled water + 
2 Ethanol + 
3 Methanol + 
4 Acetone - 
5 Chloroform - 
6 Ethyl acetate - 
7 0.1N HCl + 
8 0.1 N NaOH + 
 
 
 
λ max OF LAMIVUDINE: 
λ max of lamivudine was found to be 271.5 nm in distilled 
water. 
 
Figure 1: Scanning of Lamivudine in UV range 
Standard Curve of Lamivudine 
Standard calibration curve of lamivudine was determined by 
plotting absorbance v/s concentration on double beam U.V. 
spectrophotometer using λ max = 271.5 nm. Straight line 
was obtained after plotting concentration on X axis. It 
follows the beer’s law. As beer’s law is concentration 
dependent and on increasing the concentration from 5μg/ml 
to 30μg/ml, gave liner increase in absorbance39-40. The 
regression equation was y = 0.0247x + 0.0093, which was 
further used for calculation of concentration of unknown 
samples. The R2 value of standard curve was 0.9978, which 
signify that plot was linear.  The results are shown in table 
3and figure 1. 
Table 3: Absorbance of Lamivudine in distilled water 
at λmax 271.5 nm 
S. No. Concentration(µg/ml) Absorbance (nm)±(SD) 
1 0 0 
2 5 0.116±0.002 
3 10 0.238±0.001 
4 15 0.334±0.003 
5 20 0.493±0.002 
6 25 0.613±0.002 
7 30 0.738±0.001 
 
EVALUATION PARAMETER FOR MUCOADHESIVE GELS41: 
General Appearance 
All three gel formulations were good texture profile. They 
were transparent in appearance and no sign of grittiness was 
observed. 
Mucoadhesive Force 
Mucoadhesive force of all three gel formulations were 
determined by using goat stomach mucosa and is given in 
table 4. Out of all three polymers, Carbopol showed the 
maximum mucoadhesive force. 
Table 4: Mucoadhesive force of polymers used in gel 
formulations. 
S. No. Polymers Mucoadhesive force 
(dyne/cm²) 
1 Poloxamer 407 2.2455 
2 HPMC K15 2.6271 
3 Carbopol 934 3.3618 
 
Drug Release Study 
Drug release study data of all three gels are shown in table 5.
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Table 5:  Data of Release profile of formulated gels. 
Time (hr) 
Cumulative % drug release 
HPMC K15 gel Poloxamer 407 gel Carbopol 934 gel 
0 0 0 0 
1 18.43±1.5 12.92±2.3 4.62±1.9 
2 37.45±2.7 27.63±2.8 13.83±3.4 
3 46.45±3.8 36.6±3.5 18.8±2.2 
4 64.07±2.4 47.43±2.2 25.02±1.5 
5 73.56±4.2 59.82±3.1 34.87±1.7 
6 83.92±2.8 66.01±4.3 42.09±2.9 
7 87.12±2.1 72.32±2.4 61.83±2.6 
8 91.32±1.6 79.71±1.8 67.63±1.8 
10 94.22±1.2 83.87±1.2 73.98±2.3 
12 97.89±0.6 88.95±0.88 78.38±1.4 
The above drug release data & plot show that the prepared gel formulations released drug up to 12 hours and more or less, all 
three gel formulations were giving sustained drug release profile. These gel formulations were further studied to know the drug 
release kinetics. 
Drug release kinetic study: 
HPMC K15 gel: 
Table 1.6:  Data for drug release kinetic study of HPMC K15 gel 
Time 
(hr) 
Square 
root of 
time 
Log time 
Cumulative % 
drug released 
Log (Mt/M∞) 
Cumulative % 
drug remaining 
to release 
Log  cumulative % 
drug remaining to 
release 
0 0 - 0 - 100 2 
1 1 0 18.43 1.2655 81.57 1.9115 
2 1.414 0.301 37.45 1.5734 62.55 1.7962 
3 1.732 0.477 46.45 1.6669 53.55 1.7287 
4 2 0.602 64.07 1.8066 35.93 1.5554 
5 2.236 0.6989 73.56 1.8666 26.44 1.4222 
6 2.449 0.778 83.92 1.9238 16.08 1.2062 
7 2.645 0.845 87.12 1.9401 12.88 1.1099 
8 2.828 0.903 91.32 1.9605 8.68 0.9385 
10 3.162 1 94.22 1.9741 5.78 0.7619 
12 3.464 1.079 97.89 1.9907 2.11 0.3242 
 
Zero order 
R² 
First order 
R² 
Higuchi 
R² 
Korsmeyer- peppas 
R² n 
0.8538 0.9896 0.9598 0.9488 0.6792 
On the basis of R² values of above release kinetic plots, it was determined that the HPMC gel follows first order drug release 
kinetic model. As R² value of first order, 0.9896 was highest among all. And in Korsmeyer- peppas plot, n= 0.6792 (i.e. 
0.45<n<0.89), indicates anomalous diffusion or non-fickian diffusion. That means, release rate of the HPMC gel was controlled 
by the combination of both, diffusion and erosion release mechanism.  
Poloxamer 407 gel 
Table 1.7:  Data for drug release kinetic study of poloxamer 407 gel 
Time 
(hr) 
Square root 
of time 
Log 
time 
Cumulative % 
drug released 
Log (Mt/M∞) 
 
Cumulative % drug 
remaining to release 
Log  cumulative % drug 
remaining to release 
0 0 - 0 - 100 2 
1 1 0 12.92 1.1112 87.08 1.9399 
2 1.414 0.301 27.63 1.4413 72.37 1.8595 
3 1.732 0.477 36.6 1.5634 63.4 1.8020 
4 2 0.602 47.43 1.6760 52.57 1.7207 
5 2.236 0.6989 59.82 1.7768 40.18 1.6040 
6 2.449 0.778 66.01 1.8196 33.99 1.5313 
7 2.645 0.845 72.32 1.8615 27.68 1.4421 
8 2.828 0.903 79.71 1.9015 20.29 1.3072 
10 3.162 1 83.87 1.9236 16.13 1.2076 
12 3.464 1.079 88.95 1.9491 11.05 1.0433 
 
Zero order 
R² 
First order 
R² 
Higuchi 
R² 
Korsmeyer- peppas 
R² n 
0.9211 0.9945 0.9695 0.9725 0.7836 
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On the basis of R² values of above release kinetic plots, it was 
determined that the poloxamer gel follows first order drug 
release kinetic model. As R² value of first order, 0.9945 was 
highest among all. And in Korsmeyer- peppas plot, n= 0.7836 
(i.e. 0.45<n<0.89), indicates anomalous diffusion or non-
fickian diffusion. That means, release rate of the poloxamer 
gel was controlled by the combination of both, diffusion and 
erosion release mechanism. 
 
Zero order 
R² 
First order 
R² 
Higuchi 
R² 
Korsmeyer- peppas 
R² n 
0.9597 0.9568 0.8883 0.981 1.1678 
 
On the basis of R² values of above release kinetic plots, it was 
determined that the carbopol gel follows zero order drug 
release kinetic model. As R² value of zero order, 0.9597 was 
highest among all. And in Korsmeyer- peppas plot, n= 1.1678 
(i.e. higher than 0.89), indicates super case II transport. As 
per super Case II transport mechanism, the release 
mechanism was not significantly influenced by formulation 
variables swelling dispersed within a glassy polymer. 
Initially the polymer begin to swell in contact of water, .as 
the penetrant enters the glassy polymer , the glass transition 
temperature of the polymer is lowered and become rubbery 
show diffusion allowing relaxation of macromolecular chains 
and drug diffuse out from the swollen rubbery area of 
polymer wall (Bhowmik B.B. et al, 2009). 
Evaluation Parameter for Mucoadhesive Tablets42: 
GENERAL APPEARANCE 
General appearance was examined by visual inspection. All 
tablets were good in appearance; they were white colored 
oval shaped tablets with smooth surface texture and no 
pinholes were observed. 
WEIGHT VARIATION 
All nine tablet batches passed the weight variation test as 
percentage weight variation was within the pharmacopoeia 
limits (±5%). Results are shown table 8. 
Table 8: weight variation 
BATCH CODE WEIGHT VARIATION (mg) (N=20) RESULT 
F1 498±1.9 PASSED 
F2 497±2.6 PASSED 
F3 502±1.76 PASSED 
F4 499±1.6 PASSED 
F5 501±2.8 PASSED 
F6 497±2.9 PASSED 
F7 496±3.3 PASSED 
F8 500±1.88 PASSED 
F9 498±2.3 PASSED 
 
1. THICKNESS  
Thickness of all tablet batches is given in table 9. The 
thickness of the tablets was found in the range of 5.6– 6.1 
mm. 
Table 9: Thickness of tablets 
BATCH CODE THICKNESS (mm) (N=6) 
F1 5.8±0.18 
F2 5.9±0.177 
F3 6.1±0.076 
F4 6±0.11 
F5 5.8±0.2 
F6 5.9±0.16 
F7 5.8±0.084 
F8 6±0.15 
F9 5.9±0.23 
2. FRIABILITY 
The friability of all nine batches is given in table 1.10. 
Friability of tablets was observed in acceptable range of 
0.34-0.84%. It was within the pharmacopeia limit i.e. less 
than 1%. That means all tablets had good mechanical 
strength. 
Table 1.10: Friability of tablets. 
BATCH CODE 
FRIABILITY (%) 
(N=20) 
F1 0.84 
F2 0.76 
F3 0.72 
F4 0.69 
F5 0.63 
F6 0.56 
F7 0.48 
F8 0.46 
F9 0.34 
 
Hardness   
Hardness of all batches is given in table 11. Hardness of the 
tablets was found in the range of 6.8-9.4 kg/cm2. That was 
satisfactory for sustained release formulations and also 
indicates good mechanical strength to withstand physical 
and mechanical stress conditions while handling. 
Table 11: Hardness of tablets. 
BATCH CODE 
HARDNESS(kg/cm2) 
(N=6) 
F1 6.9±0.15 
F2 7.6±0.42 
F3 8.4±0.34 
F4 7.2±0.22 
F5 7.6±0.288 
F6 8.2±0.37 
F7 7.3±0.15 
F8 8.8±0.137 
F9 9.3±0.15 
 
Swelling Index 
Swelling studies were performed till 20 min because after 
that carbopol tablets started forming soft gel, which was 
difficult to handle and HPMC & poloxamer formulations 
showed erosion (but poloxamer tablets erode slowly then 
HPMC tablets). Results are given in table 12. 
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Table 12: Swelling studies of tablets. 
BATCH CODE 
%  swelling index (±SD) (N=3) 
Time (mins) 
1 10 20 
F1 10.2±2.3 18.6±3.7 32.1±4.2 
F2 12.4±1.8 20±3.4 46.3±2.5 
F3 15.1±2.4 24.6±2.1 54.2±3.6 
F4 13.4±2.2 21.3±4.2 43.5±2.8 
F5 17.7±1.5 32.3±5.1 49.6±2.3 
F6 22.2±2.5 40.2±3.6 57.2±4.3 
F7 27.4±1.2 75±2.6 97.7±3.8 
F8 36.7±2.4 84.6±2.1 102±4.1 
F9 39.2±1.7 90.3±3.4 116±3.3 
 
Mucoadhesive studies 
Mucoadhesive strength of tablets was measured on the 
modified physical balance as described earlier. The highest 
adhesion force and highest strength of the mucoadhesive 
bond was observed with the carbopol formulations. And it 
was increasing with increase in concentration of polymer. 
Table 13: Mucoadhesive strength & force of tablets. 
BATCH 
CODE 
MUCOADHESIVE 
STRENGTH  (g) ±SD 
MUCOADHESIVE FORCE 
(N) 
F1 17.3±1.4 0.170 
F2 21.9±0.95 0.215 
F3 24.6±0.74 0.241 
F4 20.4±1.2 0.201 
F5 23.5±1.5 0.231 
F6 27.4±0.99 0.269 
F7 33.2±2.2 0.326 
F8 37.5±2.3 0.368 
F9 42.8±1.8 0.417 
 
CONCLUSION 
The aim of present study was to formulate & evaluate the 
mucoadhesive sustained release formulations of lamivudine. 
And to fulfill this aim, two mucoadhesive formulations- gels 
and tablets were prepared by using three different 
polymers: HPMC K15, poloxamer 407 & carbopol 934. Three 
mucoadhesive gel and nine tablet formulations were 
prepared and evaluated for various parameters.  
All prepared gel & tablet formulations had good physico-
mechanical properties. Among all the formulations, carbopol 
gel and tablets showed the highest mucoadhesive force, 
although, each formulation had good adhesive force.  All 
three gels were able to give sustained release up to 12 hours. 
Tablet formulations, F1 to F5 failed to fulfill the aim. Only F6, 
F7, F8 & F9 formulations were selected, as all gave sustained 
release up to 12 hours, except F6, which gave sustained 
release profile only till 7 hours. From the drug release plots, 
it was concluded that the type of polymer and concentration 
of polymer have distinct effect on in vitro drug release 
profile. This can further be justified with in vivo studies. And 
all the formulations follow first order mechanism with 
anomalous diffusion or non-fickian diffusion, except 
carbopol gel and poloxamer tablets. Carbopol gel follows 
zero order release rate with super case II transport and 
poloxamer tablets (F6) follow higuchi with non-fickian 
diffusion. 
So from this study, it is concluded that mucoadhesive 
formulations of lamivudine can be prepared for sustaining 
its release. And the successful outcome of the present study 
also encourage for further studies to assess the ability of the 
mucoadhesive formulations of lamivudine in providing an 
effective sustained and safe therapy for AIDS.  
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